Bone Therapeutics and Implant Therapeutics have signed a research evaluation agreement to enable Bone Therapeutics to access, evaluate and materially transfer Implant Therapeutics’ Induced Pluripotent Stem Cell (iPSC) lines, media, differentiation protocols and expertise. Bone Therapeutics has developed a bone marrow-derived off-the-shelf, allogeneic MSC cell therapy platform. Its allogeneic cell therapy product, ALLOB, currently in […]